The Future of GI Oncology: Innovations and Collaborations

In this episode of Meet the Greek, Dr. Petros Grivas and Dr. David Zhen discuss the latest advancements in gastrointestinal cancers, focusing on gastroesophageal and neuroendocrine cancers. They explore the exciting new therapies and clinical trials that are changing the landscape of treatment, the importance of collaboration with community oncology, and the role of genetic factors in cancer predisposition. The conversation also highlights the significance of a multidisciplinary approach in patient care and the growing need for survivorship programs as more patients live longer after treatment. Looking ahead, they discuss future directions in GI oncology, including the potential for de-escalation of therapies and the integration of novel treatments. Takeaways There has been significant momentum in GI cancer treatments recently. New therapies include immunotherapies and CAR-T therapies. Collaboration with community oncology is essential for patient care. Genetic predisposition plays a crucial role in cancer management. Young onset colorectal cancer is on the rise. Multidisciplinary teams are vital for effective treatment. Survivorship programs are becoming increasingly important. Clinical trials are essential for advancing cancer treatment. De-escalation of therapies may improve patient outcomes. The future of GI oncology looks promising with novel therapies.